Navigation Links
At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed)

WASHINGTON, DC, June 11, 2007 /PRNewswire-FirstCall/ - Paul S. Aisen, M.D., Professor of Neurology and Medicine at Georgetown University Medical Center, and principal investigator in the United States of Neurochem Inc.'s North American Phase III clinical trial for tramiprosate (ALZHEMED(TM)) will present today an update on Neurochem's investigational product candidate for the treatment of Alzheimer's disease (AD). The presentation by Dr. Aisen will take place at the Intervention and Treatment Session, scheduled from 2:30 - 4:30 P.M. (ET), at the Alzheimer's Association International Conference on Prevention of Dementia in Washington, DC. In his presentation entitled, A Phase III Study of the Efficacy, Safety and Disease Modification Effect of Tramiprosate in Mild-to-Moderate Alzheimer's Disease, Dr. Aisen will review the Phase III clinical trial and provide an update.

Neurochem announced in April 2007 that an adjustment to the initial statistical model, as set out in the statistical plan, would be necessary to provide accurate results. The procedure to arrive at a reliable model involves a detailed analysis of potential confounding factors, and Dr. Aisen will present on the progress to date. In addition, Dr. Aisen will provide an update on the progress in the analysis of the Phase III clinical trial primary endpoint data. Some preliminary descriptive data shows numerical differences in favor of tramiprosate (ALZHEMED(TM)) on the primary clinical endpoint and also shows differences between groups on the primary disease modification endpoint as measured by magnetic resonance imaging (MRI). However, work regarding the adjustment of the statistical model is ongoing and, therefore results of the Phase III clinical trial cannot be derived from the preliminary data nor can statistical significance be assigned at this time. Accordingly, no predictions or conclusions can yet be made regarding the outcome of the Phase III study.






Page: 1 2 3 4

Related medicine technology :

1. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
2. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
3. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
6. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
7. Clinical Update - Debio 9902 (ZT-1) for Alzheimers Disease
8. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
9. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
10. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
11. Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimers Drug
Post Your Comments:
(Date:4/24/2015)...  Elekta has CE marked the latest version (v5.10) ... enabling European clinics to deliver a sophisticated radiation therapy ... 3D planning, IMRT, VMAT and stereotactic planning – all ... Monaco ® v5.10 provides significant planning ... in 3D planning as well as the addition of ...
(Date:4/23/2015)... April 23, 2015  ResMed Inc. (NYSE: RMD ... 31, 2015.  Revenue for the quarter was $422.5 million, ... March 31, 2014 (a 13 percent increase on a ... increase of 1 percent compared to the quarter ended ... quarter were $0.64, an increase of 2 percent compared ...
(Date:4/23/2015)... April 23, 2015 Nektar Therapeutics (Nasdaq: NKTR ... ended March 31, 2015 on Thursday, April 30, 2015, after ... president and chief executive officer, will host a conference call ... (ET)/2:00 p.m. Pacific Time (PT). The press ... can be accessed through a link that is posted on ...
Breaking Medicine Technology:Elekta CE marks for Monaco v5.10 treatment planning system 2ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 11ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 12ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 13Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After Close of U.S.-Based Financial Markets 2
... 5, 2011 Express Scripts contributed more than $226 ... economic analysis of the company,s data by a university ... The economic impact study, presented today to state economic ... support 2,665 direct and indirect jobs in the state. ...
... NeuroVasx announced today that the FDA ... Humanitarian Use Device (HDE) for the treatment of large, ... most difficult to treat.  The HDE allows for the ... the U.S. (Logo: http://photos.prnewswire.com/prnh/20110405/CG77724LOGO ) ...
Cached Medicine Technology:Express Scripts Injects $226 Million Into Arizona Economy, Study Finds 2NeuroVasx Receives FDA Approval for cPAX Aneurysm Treatment System 2
(Date:4/26/2015)... Italian public health researchers have released new data ... and other asbestos-related industries. Surviving Mesothelioma has just posted ... to read it now. , University researchers ... Medicine analyzed more than 15,000 cases of mesothelioma between ... asbestos cancer was most common. , “Asbestos cement ...
(Date:4/26/2015)... (PRWEB) April 26, 2015 From March ... and his wife, Trivedi Master™ Dahryn Trivedi, spent a ... approved research laboratories and institutions in the efforts of ... medicine and nutraceutical supplements for human health care. ... different research labs and institutions. All lab facilities are ...
(Date:4/26/2015)... Rosa, CA (PRWEB) April 26, 2015 In ... from Washington State University evaluated the head-neck biomechanics occurring during ... of the study were able to determine that use of ... much as 3 to 5 times - more than when ... surprising outcome for such a study, but pointing out the ...
(Date:4/25/2015)... April 26, 2015 The National ... , a national endeavor to prepare nurses to provide ... a great success, according to a new report by ... original funding partners. , The project began in ... (CCP), under the direction of Elaine Tagliareni, EdD, RN, ...
(Date:4/25/2015)... The Hon. Ellen Tauscher, Independent Chair of the ... following the deadly earthquake in Nepal: , "Today a ... deaths of more than 1,000 people. The aftershocks ... India and other parts of South Asia. I ... of Nepal and the families of the victims. ...
Breaking Medicine News(10 mins):Health News:New Investigation Finds Mesothelioma “Clusters” Around Italian Cement Plants, According to Surviving Mesothelioma 2Health News:Trivedi Science™ Has Started Scientific Research to Create More Effective Pharmaceuticals and Nutraceuticals 2Health News:Trivedi Science™ Has Started Scientific Research to Create More Effective Pharmaceuticals and Nutraceuticals 3Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 3Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 4Health News:Hartford Foundation Report Details Success of NLN's Advancing Care Excellence for Seniors (ACE.S) Program 2Health News:Hartford Foundation Report Details Success of NLN's Advancing Care Excellence for Seniors (ACE.S) Program 3
... Canadian television viewers will get,a chance to learn ... the,documentary "The Brain That Changes Itself" airs on the ... book of the same name by,author Norman Doidge, MD, ... and features the science, scientists, products and,customers of Posit ...
... Service Reductions , , WASHINGTON, Dec. ... Care (CQRC) -- an alliance of the country,s leading home oxygen ... oxygen beneficiaries -- are anxiously preparing for massive Medicare cuts to ... , , The Medicare Part ...
... feel better mentally, physically, researchers say , , WEDNESDAY, Dec. ... to work out their anger with exercise, a new ... otherwise healthy 7- to 11-year-olds found they reduced both ... a 10- to 15-week after-school aerobic exercise program. The ...
... Dec. 3 Many dentists and dental office,staff ... however, very,few dental professionals have taken advantage of ... while offering,the convenience of determining benefit information while ... "Paper submissions typically ...
... new release of HeartScore the interactive tool designed to ... and stroke in Europe created by the European Society ... 2008 at www.HeartScore.org . , This revised version ... patient data history and progress monitoring. Three formats are ...
... Dec. 3 New footage released today from an undercover ... staff deliberately violating the state,s mandatory reporting laws for sexual ... shows Lila Rose, a UCLA student journalist and ... 13-year-old girl. In an appointment with a Planned Parenthood nurse, ...
Cached Medicine News:Health News:Posit Science Featured in Canadian Documentary on the Brain 2Health News:Home Oxygen Community Braces for Massive Cuts to Medicare's Home Oxygen Benefit Starting January '09 2Health News:Home Oxygen Community Braces for Massive Cuts to Medicare's Home Oxygen Benefit Starting January '09 3Health News:Electronic Submission for Dental Predeterminations May Increase Efficiency, Patient Satisfaction 2Health News:The ESC launches a new release of HeartScore 2Health News:The ESC launches a new release of HeartScore 3Health News:Live Action: New Video Shows Indiana Planned Parenthood Covering Up Rape of 13-year old Girl 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: